VitabalansOy
Updating the operating model
- Biotechnology
- January 2026
A4BEE prepared this analysis from publicly available sources. It reflects our own reading of VitabalansOy's published strategy and is not endorsed by, or produced in cooperation with, VitabalansOy. Company website
Strategic priorities
VitabalansOy operates across 4 stated priorities, with the most concrete near-term plan anchored on capacity expansion.
Construction of a significant new production facility in Hameenlinna to double or triple production capacity for European market penetration while maintaining Finnish quality standards.
Modernization of tableting and packaging capabilities with state-of-the-art machinery (Prexima 300, Effecta coating pan) to resolve throughput-vs-quality bottlenecks.
Maintaining all R&D, production, and registration functions in a single Finnish hub to ensure GMP/Oiva compliance across 147 product variants.
-
01
Capacity Expansion
Construction of a significant new production facility in Hameenlinna to double or triple production capacity for European market penetration while maintaining Finnish quality standards.
-
02
Operational Excellence
Modernization of tableting and packaging capabilities with state-of-the-art machinery (Prexima 300, Effecta coating pan) to resolve throughput-vs-quality bottlenecks.
-
03
Centralized Quality Control
Maintaining all R&D, production, and registration functions in a single Finnish hub to ensure GMP/Oiva compliance across 147 product variants.
-
04
Pan-European Market Dominance
use the "Key Flag" Finnish brand and integrated distribution network (including Blanco Pharma acquisition) to capture premium positions in Germany, Poland, and Nordic markets.
Challenges we see
- Operations Manufacturing
Legacy Equipment Bottlenecks
Older tablet press machines cannot deliver the high compression forces (up to 100 kN) required for certain formulations without drastically reducing production speed, forcing a trade-off between manufacturing velocity and product integrity.
Overall Equipment Effectiveness (OEE) is compromised as the plant must choose between throughput and quality, limiting capacity utilization during peak demand periods.
- Digital Integration
Data Islands and IT/OT Disconnect
New machinery like the Prexima 300 features advanced autoregulation loops and real-time monitoring, but this data remains trapped within proprietary machine interfaces, preventing site-wide optimization and predictive maintenance.
Leadership has no real-time, granular visibility into production costs and efficiency across all three Hameenlinna plants, hindering data-driven decision-making.
- Compliance Regulatory
Manual Batch Recording and Compliance Overhead
Without a comprehensive Manufacturing Execution System (MES), the link between ERP and shop floor is manual, involving paper-based batch records that require time-consuming verification before product release.
Manual data entry increases error risk and slows time-to-market, while dual GMP/Oiva compliance requirements multiply validation overhead for any digital system changes.
- Operations Operations
Workforce Scaling and Knowledge Transfer
The company relies heavily on specialized, internally-trained staff to operate complex pharmaceutical manufacturing equipment, but the open market lacks readily available technicians with the required Finnish pharmaceutical expertise.
As the new factory comes online, demand for qualified technicians will outstrip the capacity of internal training programs, creating a critical personnel bottleneck.
- ESG Compliance
ESG Reporting and Sustainability Data Gap
EU regulations will increasingly require detailed Environmental, Social, and Governance reporting including energy consumption, water waste, and carbon footprint per batch produced by 2030.
Without automated data acquisition systems, generating sustainability reports requires significant manual labor, risking regulatory compliance gaps and erosion of the premium Finnish brand.
Opportunities, by urgency and business impact
Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.
-
Disconnected Production Data
Valuable production metrics from modern machinery like the Prexima 300 are trapped in proprietary interfaces, creating data islands that prevent comprehensive OEE analysis, predictive maintenance, and site-wide optimization across three production plants.
Implement a unified Industrial Data Platform using OPC UA protocols to connect all machinery into a single source of truth, enabling real-time visibility, predictive maintenance, and data-driven scheduling across 147 product lines.
-
Manual Quality Verification Bottleneck
Quality assurance teams must manually verify paper-based batch records before product release, creating delays in time-to-market and introducing human error risk in a GMP-regulated environment handling 147 product variants.
Deploy an integrated MES with electronic batch records and AI-driven vision systems to automate quality oversight, eliminate manual weight checks, and achieve 100% automated quality verification while maintaining full regulatory compliance.
-
New Factory Digital Architecture Gap
The new greenfield production facility under construction represents a massive CAPEX commitment, but without proper digital architecture planning, it risks becoming another collection of disconnected systems rather than a Digital-First pharmaceutical facility.
Design the digital architecture for the new factory from day one using ontology-based data models and MTP (Module Type Package) standards, ensuring every machine speaks a common language and integrates smooth with corporate systems.
-
Technician Training and Onboarding Bottleneck
The specialized skill set required for Finnish pharmaceutical manufacturing is not readily available in the open market, and internal training programs cannot scale fast enough to support new factory staffing requirements.
Implement AR/VR-enabled digital work instructions and training platforms to accelerate onboarding of new production technicians, reduce training time by 40-60%, and capture institutional knowledge from experienced staff.
-
Cybersecurity and OT Network Vulnerability
As industrial systems become more connected for Industry 4.0 initiatives, legacy air-gapped hardware becomes increasingly vulnerable, creating both regulatory (NIS2/IEC 62443) and safety risks for pharmaceutical production.
Conduct a comprehensive Cyber-Physical Risk Audit and implement secure OT network segmentation that protects production systems from corporate network breaches while enabling safe data integration for digital transformation.
What we'd propose
- Enterprise AI
Industrial Data Platform Implementation
Deploy a unified, ontology-based Industrial Data Platform that connects all production machinery across Hameenlinna's three plants and the new facility into a single source of truth for real-time OEE monitoring, predictive maintenance, and operational optimization.
-
Ontology layer
DETAIL
-
Predictive models
DETAIL
-
Decision surfaces
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital CDMO
Digital Manufacturing Excellence Program
Transform the new greenfield factory into a Digital-First pharmaceutical facility by designing Industry 4.0 architecture from the ground up, integrating MES, digital batch records, and automated quality systems.
-
OT/IT convergence
DETAIL
-
Batch intelligence
DETAIL
-
Production release flow
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital CDMO
Legacy Equipment Retrofitting and Integration
Bring legacy production lines into the digital ecosystem through sensor retrofitting and data acquisition solutions, enabling unified monitoring alongside modern IMA Active machinery without full equipment replacement.
-
OT/IT convergence
DETAIL
-
Batch intelligence
DETAIL
-
Production release flow
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital CDMO
AR/VR Training and Knowledge Management Platform
Implement augmented reality work instructions and virtual reality training simulations to accelerate technician onboarding, capture institutional knowledge, and scale workforce development for new facility staffing.
-
OT/IT convergence
DETAIL
-
Batch intelligence
DETAIL
-
Production release flow
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital CDMO
OT Cybersecurity and Network Segmentation
Conduct comprehensive cyber-physical risk assessment and implement secure OT network architecture ensuring NIS2/IEC 62443 compliance while enabling safe Industry 4.0 connectivity for production systems.
-
OT/IT convergence
DETAIL
-
Batch intelligence
DETAIL
-
Production release flow
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
Digital maturity: today and target
Scored out of 100 across six dimensions. The target is what VitabalansOy's own published ambition implies — not a perfect score.
- Data Integration 35 → 85
- Modern machinery has advanced sensors but data remains trapped in proprietary silos; new platform needed for site-wide visibility
- Process Automation 45 → 90
- New Prexima 300 features autoregulation but legacy lines require manual intervention; MES and automated QC needed
- Predictive Analytics 20 → 75
- No documented predictive maintenance or AI-driven quality control; significant opportunity for ML implementation
- Workforce Enablement 40 → 80
- Strong internal training culture but manual/traditional methods; AR/VR can dramatically accelerate knowledge transfer
- Cybersecurity Posture 30 → 85
- Legacy air-gapped systems becoming connected without formal OT security framework; NIS2 compliance required
- Sustainability Tracking 25 → 80
- No automated ESG data acquisition; manual labor required for sustainability reporting ahead of 2030 EU mandates
Check this yourself
Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.
-
Self-assessment
Data & AI Maturity
See how ready your data actually is for the AI work you're planning.
-
Self-assessment
Electronic Batch Record (eBR) Readiness
Check how far your batch records are from paperless, and what the next step is.
-
Market comparison
Pharma Data Platform Use Cases — Ranked
Use cases ranked by how hard they are against what they're worth.
-
Market comparison
European CDMOs Compared
The 2026 landscape: who does what, at what scale.
Think we've read this right?
Talk to usRelated reading
-
OPC UA protocol support in embedded systems
OPC Unified Architecture (OPC UA) is a modern standard for data exchange, increasingly used in industrial environments.
-
Accelerating lab and manufacturing operations with MTP – a modular approach
Among the various modular and plug-n-produce approaches, the Modular Type Package (MTP) approach has emerged as a game-changer.
-
Cybersecurity for industrial automation and control systems in Life Sciences
Pharma specific hardware and software development is far more complex than only Cybersecurity, but securely designed Product may address...
-
From Paper to Performance: Operational Efficiency and Compliance in Labs
Transform your QC lab with scalable digital solutions that embed compliance, boost efficiency, and deliver a future-ready competitive edge.
-
Digital Twin Maturity Model – self-assessment tool
Initially, defining what a digital twin even is seemed simple - we have a real product and its virtual counterpart, and we combine the two.
This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with VitabalansOy, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].